🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

29 recruiting trials

for CLDN18.2 Positive

Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer NCT06962137Phase 26 sites📍 Antwerp📍 Brussels📍 Brussels Universitaire Ziekenhuizen KU Leuven · Tests: zolbetuximab, Retrospective cohort, no intervention SG1906 for CLDN18.2-Positive Solid Tumors NCT05857332Phase 19 sites📍 Beijing📍 Xiamen📍 Guangzhou Hangzhou Sumgen Biotech Co., Ltd. · Tests: SG1906 LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study NCT07556640Phase 21 site📍 Shanghai Ruijin Hospital · Tests: LM-302, S-1, paclitaxel, LM-302, Cadonilimab, S-1, paclitaxel Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma NCT07569068Phase 21 site📍 Shanghai Ruijin Hospital · Tests: Tislelizumab, LM-302 and S-1, Tislelizumab combined with oxaliplatin and S-1 A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer NCT06901531Phase 3252 sites📍 Birmingham📍 Bakersfield📍 Cerritos Astellas Pharma Global Development, Inc. · Tests: zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent) IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma NCT07483567Phase 21 site📍 Beijing Innovent Biologics (Suzhou) Co. Ltd. · Tests: IBI343,sintilimab,oxaliplatin,S-1, sintilimab,oxaliplatin,S-1 QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ NCT07716449Phase 31 site📍 Beijing Qilu Pharmaceutical Co., Ltd. · Tests: QLS31905, Sintilimab, Oxaliplatin, Capecitabine IBI343 in Combination Therapy for Advanced Malignant Solid Tumors NCT07483554Phase 21 site📍 Hangzhou Innovent Biologics (Suzhou) Co. Ltd. · Tests: IBI343,Gemcitabine, Albumin-bound Paclitaxel A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors NCT07460375Phase 1, Phase 28 sites📍 Boston📍 Lake Success📍 Charleston LigaChem Biosciences, Inc. · Tests: LCB02A Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 NCT07431281Phase 3314 sites📍 Birmingham📍 Mobile📍 Anchorage AstraZeneca · Tests: Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, 5-Fluorouracil SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor NCT06350006Phase 11 site📍 Guangzhou Shanghai Hengrui Pharmaceutical Co., Ltd. · Tests: SHR-A1904; Adebrelimab, SHR-A1904; CAPOX; Adebrelimab Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) NCT07432295Phase 26 sites📍 Goodyear📍 Duarte📍 Boston I-Mab Biopharma US Limited · Tests: Givastomig, Nivolumab, 5Fluorouracil, Leucovorin, Oxaliplatin Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma NCT07622940Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EBNK-1822H2 dual-target CLDN18.2/HER2 CAR-NK cells, Fludarabine, Cyclophosphamide A IIT Study of 177Lu-DOTA-SNA040 NCT07595237EARLY Phase 11 site📍 Shanghai SmartNuclide Biopharma · Tests: 177Lu-DOTA-SNA040 ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer NCT07444541Phase 1, Phase 23 sites📍 Los Angeles📍 Plantation📍 San Antonio Anova Innovation Limited · Tests: ANO31905, AG [gemcitabine+nab-paclitaxel], mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil] A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors NCT05205850Phase 1, Phase 22 sites📍 Shanghai📍 Hangzhou RemeGen Co., Ltd. · Tests: RC118-ADC An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors NCT07680257EARLY Phase 11 site📍 Hefei Celest Therapeutics (Shanghai) Co., Ltd. · Tests: SUV2208A cell injection, SUV2208A, SUV2208A A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients NCT07103668Phase 31 site📍 Beijing Suzhou Immunofoco Biotechnology Co., Ltd · Tests: CAR T cells, Control Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma NCT07872722Phase 24 sites📍 Saitama📍 Tokyo📍 Tokyo National Cancer Center, Japan · Tests: Zolbetuximab, Durvalumab, FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma NCT07795346Phase 3131 sites📍 Bengbu📍 Fuyang📍 Hefei Antengene Biologics Limited · Tests: ATG-022, Docetaxel or Irinotecan Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma NCT07427992n/a1 site📍 Milan European Institute of Oncology A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study NCT05934331Phase 21 site📍 Shanghai LaNova Medicines Zhejiang Co., Ltd. · Tests: LM-302, Toripalimab, Capecitabine, Tegafur, Gimeracil and Oteracil Potassium Capsules, Nivolumab Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. NCT07385703Phase 3106 sites📍 Hefei📍 Hefei📍 Hefei Shanghai Chia Tai Tianqing Pharmaceutical Technology Develo… · Tests: LM-302 Injection, Tislelizumab, Oxaliplatin Injection, Capecitabine Tablets A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer NCT07450976Phase 22 sites📍 Beijing📍 Shanghai Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-A1904 for Injection The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma NCT06587425Phase 21 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: LM-302+Candonilimab+Capecitabine JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma. NCT07284134Phase 368 sites📍 Hefei📍 Beijing📍 Beijing Shanghai Junshi Bioscience Co., Ltd. · Tests: JS107 for Injection, Irinotecan, Paclitaxel, Docetaxel Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors NCT06084286Phase 11 site📍 Chengdu Sichuan University · Tests: Dual-targeting CLDN18.2 and PD-L1 CAR-T cells JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma NCT07584135Phase 31 site📍 Guangzhou NingBo Junyan Hongshi Biosciences Co., Ltd · Tests: Injection JS107&Toripalimab& Oxaliplatin Injection& Capecitabine, Sintilimab& Oxaliplatin Injection&… Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis NCT06519591Phase 21 site📍 Shanghai Ruijin Hospital · Tests: Cadonilimab, LM-302, S-1, paclitaxel
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy